{"id":"W2553125824","doi":"10.1182/blood.v116.21.2290.2290","title":"Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Imatinib; Internal medicine; Myeloid leukemia; Adverse effect; Imatinib mesylate; Population; Tyrosine-kinase inhibitor; Oncology; Gastroenterology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005887681,0.0001931749,0.0004673367,0.000263445,0.0001707689,0.0003889289,0.0001994576,0.0002260676,0.001082843],"category_scores_gemma":[0.0006220805,0.00007158525,0.0003963401,0.0004004078,0.0002320986,0.0002529161,0.0002661836,0.000391641,0.0001494427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002674734,"about_ca_system_score_gemma":0.0004129975,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005081175,"about_ca_topic_score_gemma":0.0009484049,"domain_scores_codex":[0.9997509,0.00005761961,0.00003047102,0.00005588446,0.00005394593,0.00005113566],"domain_scores_gemma":[0.9994107,0.0001454062,0.0002832937,0.00003542223,0.00003473926,0.00009034391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.0239775,0.001330161,0.8367866,0.0004271265,0.0004103399,0.002370065,0.0001876064,0.001812889,0.03909156,0.0002792115,0.001353386,0.09197347],"study_design_scores_gemma":[0.001620691,0.0233155,0.948585,0.0000707118,0.0003524971,0.006372851,0.0002695981,0.004036914,0.008768125,0.0003283774,0.006255423,0.00002442737],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982344,0.0003497886,0.0002668437,0.00003029899,0.000003406924,0.00007271713,0.0005543884,0.000005950247,0.0004821877],"genre_scores_gemma":[0.997892,0.0001533359,0.0003554772,0.00006590549,0.00001097831,0.00006358066,0.001326593,0.000001977156,0.0001303107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001082843,"threshold_uncertainty_score":0.003622472,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009099521023974712,"score_gpt":0.2515323980287856,"score_spread":0.2424328770048109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}